| Personal Touch Home Care Of Indiana Inc | |
| 139 W Tate St Ste 1, Lawrenceburg, Indiana 47025 | |
| (812) 637-5428 | |
| Name | Personal Touch Home Care Of Indiana Inc |
|---|---|
| Location | 139 W Tate St Ste 1, Lawrenceburg, Indiana |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Home Health Aide |
| Medicare ID | 157545 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 47001, 47003, 47006, 47010, 47011, 47012, 47016, 47017, 47018, 47020, 47022, 47023, 47024, 47025, 47030, 47031, 47032, 47036, 47037, 47038, 47040, 47041, 47042, 47043, 47060, 47353 |
| NPI Number | 1922087337 |
| Organization Name | PERSONAL TOUCH HOME CARE OF INDIANA, INC. |
| Address | 139 W Tate Street, Lawrenceburg, IN 47025 |
| Phone Number | 812-637-5428 |
News Archive
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
The promise of cost and clinical benefits are spurring the penetration of imaging modalities in cardiac applications. While demographics are favouring market growth, cardiac imaging device manufacturers will have to focus on innovative, patient-friendly products that promote greater safety and easier operability.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
› Verified 2 days ago
| Quality Rating: |
News Archive
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
The promise of cost and clinical benefits are spurring the penetration of imaging modalities in cardiac applications. While demographics are favouring market growth, cardiac imaging device manufacturers will have to focus on innovative, patient-friendly products that promote greater safety and easier operability.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
› Verified 2 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 99.7 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.8 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.8 | 99.6 |
| How often the home health team checked patients for depression | 98 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 86.3 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 82.1 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99 | 96.4 |
News Archive
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
The promise of cost and clinical benefits are spurring the penetration of imaging modalities in cardiac applications. While demographics are favouring market growth, cardiac imaging device manufacturers will have to focus on innovative, patient-friendly products that promote greater safety and easier operability.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
› Verified 2 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 82.5 | 79.6 |
| How often patients got better at getting in and out of bed | 77.3 | 81.1 |
| How often patients got better at bathing | 88.4 | 82.3 |
| How often patients’ breathing improved | 89.5 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 87.6 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 77.2 | 75 |
| How often home health patients had to be admitted to the hospital | 16.4 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 11.7 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 57.8 | 94 |
News Archive
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
The promise of cost and clinical benefits are spurring the penetration of imaging modalities in cardiac applications. While demographics are favouring market growth, cardiac imaging device manufacturers will have to focus on innovative, patient-friendly products that promote greater safety and easier operability.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
› Verified 2 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
The promise of cost and clinical benefits are spurring the penetration of imaging modalities in cardiac applications. While demographics are favouring market growth, cardiac imaging device manufacturers will have to focus on innovative, patient-friendly products that promote greater safety and easier operability.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
› Verified 2 days ago
The patient survey data of Personal Touch Home Care Of Indiana Inc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 90 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 89 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 82 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 87 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 81 | 78 |
News Archive
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
The European Union has funded a 4 year project called TAILORED-Treatment with € 6.000.000,-. The main goal of TAILORED -Treatment is to establish a strategy that can be used to increase the effectiveness of antibiotic treatment, reduce any potential side-effects of therapy, and help limit the emergence of antimicrobial resistance in hospitalized children and adults. The project will be coordinated by Erasmus MC, Rotterdam, the Netherlands.
The promise of cost and clinical benefits are spurring the penetration of imaging modalities in cardiac applications. While demographics are favouring market growth, cardiac imaging device manufacturers will have to focus on innovative, patient-friendly products that promote greater safety and easier operability.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
› Verified 2 days ago
Dearborn County Hospital Home Health & Hospice Location: 370 Bielby Rd, Lawrenceburg, Indiana 47025 Ratings: Phone: (812) 537-8192 | |
Personal Touch Home Care Of Indiana Inc Location: 139 W Tate St Ste 1, Lawrenceburg, Indiana 47025 Ratings: Phone: (812) 637-5428 | |
Interim Healthcare Of Se Indiana Inc Location: 500 W Eads Pkwy, Lawrenceburg, Indiana 47025 Ratings: Phone: (812) 537-5546 |